These findings support the results from other studies, which show that in women diagnosed with HER2 positive breast cancer under the age of 30 years with a family history of LFS, indicating that HER2 amplification may be a useful marker in identifying TP53 mutation carriers. The gene discussed is ERBB2; the disease is breast cancer.